Australia markets open in 5 hours 39 minutes

Valneva SE (INRLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
10.84+1.17 (+12.10%)
As of 01:18PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close9.67
Open10.84
BidN/A x N/A
AskN/A x N/A
Day's range10.84 - 10.84
52-week range7.85 - 33.35
Volume200
Avg. volume658
Market cap1.3B
Beta (5Y monthly)0.93
PE ratio (TTM)N/A
EPS (TTM)-0.74
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Financial Times

    Pfizer tests vaccine to fend off spread of tick-borne Lyme disease

    US drugmaker and French partner begin late-stage trial with 14% of global population showing evidence of infection

  • Business Wire

    Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

    NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.

  • GlobeNewswire

    VALNEVA - Declaration of shares and voting rights - July 31, 2022

    VALNEVA Declaration of shares and voting rights July 31, 2022__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: August 4, 2022 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change was